ConcertAI is the global leader in precision oncology, integrating AI technology, real-world data and real-world evidence solutions for life science companies and healthcare providers.
CEO, ConcertAIWatch Video
Jeff Elton, Ph.D., is CEO of ConcertAI, a SymphonyAI portfolio company, and a 3rd generation Real World Evidence company that partners with the American Society of Clinical Oncology’s CancerLinQ initiative and healthcare providers across the U.S. Concerto develops engineered Real-World Data products designed for specific use cases ranging from regulatory submissions, post approval studies leading to label modifications and market access initiatives. Concerto’s engineered datasets are deployed in a clinical cloud environment, with AI metadata, AI Models and AI-enabled applications all aligned to generate “precision evidence” required for high priority use cases.
Jeff Elton, Ph.D., is CEO of ConcertAI, a SymphonyAI portfolio company. Prior to Concerto, Dr. Elton was Managing Director, Accenture Strategy/Patient Health, where he focused on building the next generation of value and outcomes-centric business models for healthcare organizations and life science companies. He is the co-author of the widely cited book, <em>Healthcare Disrupted</em> (Wiley, 2016).
Jeff has over 25 years of experience as a global executive and consultant in the healthcare and life sciences. He was previously Senior Vice President of Strategy and Global Chief Operating Officer at Novartis Institutes of BioMedical Research, Inc.; founding CEO of an oncology molecular diagnostics and therapeutic pathways company; and founding board member and senior advisor to several early stage companies in Artificial Intelligence, Digital Pathology, Parkinson’s Disease treatment, protein therapeutics, diabetes, oncology therapeutics, and precision medicine/oncology diagnostics.
Jeff is currently a board member of the Massachusetts Biotechnology Council. He is a former partner with McKinsey & Company and was adjunct faculty at Boston University, Questrom School of Business, in Health Sector Management. Jeff has a Ph.D. and M.B.A. from The University of Chicago, Booth School of Business.
Precision Health Informatics and ConcertAI to Collaborate on Advanced Precision Medicine Solutions
ConcertAI Announces Expanded Collaboration with Pfizer to Accelerate Real-World Evidence and AI Technologies for Additional Disease Areas
ConcertAI to Showcase 1st End-to-End RWD and AI Technology Framework for Life Sciences and RWE Solutions at ASCO 2019
Astellas and ConcertAI to Launch Real-World Evidence Initiative on Acute Myeloid Leukemia Focused on Improving Patient Treatment and Outcomes
Bristol-Myers Squibb and ConcertAI Announce Strategic Agreement to Broaden Uses of Real-World Evidence and Accelerate Precision Oncology Innovations
CancerLinQ LLC, ConcertAI, and Tempus are Expanding Collaboration with U.S. Food and Drug Administration on Checkpoint Inhibitors
cancer reduction goal by 2029
unique patient records
year-over-year growth 2019-2020
of the top 20 life science companies use ConcertAI
We are looking forward to expanding our collaboration with ConcertAI and exploring the application of analytics to RWD (real-world data) for generating RWE (real-world evidence) in genitourinary cancers, a key area of our oncology strategy.
Using data from Texas Oncology’s large patient base, Precision Health Informatics is at the forefront of precision medicine, innovative cancer testing and diagnostic approaches, such as next-generation sequencing – changing and improving the standard of care for patients. Ultimately, this is all about developing and connecting cancer patients to precise, effective treatment. ConcertAI’s deep expertise in research-grade RWD solutions and AI technologies make it the ideal collaborator with Precision Health Informatics to help us more quickly develop medical innovations that benefit patients in our practice and elsewhere.